Cel-Sci Corp (CVM) Stock Price, Quote & News

Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune syste...

Industry: Biotechnology

Sector: Healthcare

Phone: 703 506 9460

Website: cel-sci.com

Address:

8229 Boone Boulevard, Suite 802, Vienna, United States

Dirk1969 Sep. 8 at 8:27 AM

$CVM #CVM #NYSE CEL-SCI: Multikine's Breakthrough Approvals and Saudi Market Entry From First Berlin Equity Research, dated September 1, 2025, provides a "BUY" rating for CEL-SCI Corporation, a US immuno-therapeutic biotech company. The core of the analysis focuses on Multikine, CEL-SCI's lead drug candidate for head and neck squamous cell carcinoma (HNSCC). The report details the #FDA's approval of Multikine's confirmatory trial protocol and the company's strategic moves into the Saudi Arabian market through a Breakthrough Medicine Designation application and a partnership with Dallah Pharma. It highlights Multikine's unique competitive position for patients with low PD-L1 expression, differentiating it from other therapies, and also provides a financial update with projections and a revised price target of USD 60.00. https://www.dropbox.co

0 · Reply

A416 Sep. 8 at 2:34 AM

$CVM Multikine&#39;s Breakthrough Approvals and Saudi Market Entry. https://youtu.be/dhGTQbVFyuE

1 · Reply

CurlingCalls Sep. 7 at 11:46 PM

$CVM

0 · Reply

CurlingCalls Sep. 7 at 11:45 PM

$CVM so what do we got this week? Besides IPOs of course

0 · Reply

Dirk1969 Sep. 7 at 5:52 PM

$CVM https://www.sec.gov/ix?doc=/Archives/edgar/data/0000725363/000165495425009966/cvm_8k.htm

0 · Reply

Dirk1969 Sep. 7 at 5:33 PM

$CVM ✅📈 https://youtu.be/u3vhTLg62-w?si=YzjblXe3fbeWKD1R

0 · Reply

Dirk1969 Sep. 7 at 5:30 PM

$CVM scroll through👇🏽 https://www.corporateprofile.com/media/

0 · Reply

Dirk1969 Sep. 7 at 5:25 PM

$CVM 🔥https://www.linkedin.com/posts/laurel-moody-686a7412_cvm-cel-sci-corporation-reported-that-breakthrough-activity-7366140825061302274-t_XB?utm_source=social_share_send&utm_medium=android_app&rcm=ACoAABzly-wBhTDmjZDtdXATSz4-_wlTP7M-3v0&utm_campaign=copy_link✅📈🔥

1 · Reply

cruiser24 Sep. 7 at 12:40 AM

$CVM Perhaps it would serve you well to do some research on Dallah-pharma

0 · Reply

cruiser24 Sep. 7 at 12:24 AM

$CVM Aging like a fine wine. Just waiting for the right time to pop the cork. BULLISH

1 · Reply

CEL-SCI Announces Closing of $10 Million Public Offering

Aug 27, 2025, 10:35 PM EDT - 11 days ago

CEL-SCI Announces Pricing of $10 Million Public Offering

Aug 27, 2025, 5:25 PM EDT - 11 days ago

CEL-SCI Announces Proposed Public Offering

Aug 14, 2025, 10:45 AM EDT - 24 days ago

CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results

Aug 13, 2025, 9:15 AM EDT - 25 days ago

CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline

Jul 14, 2025, 4:05 PM EDT - 7 weeks ago

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

Jul 11, 2025, 12:16 PM EDT - 2 months ago

CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules

Jul 11, 2025, 9:15 AM EDT - 2 months ago

CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer

Jun 18, 2025, 9:00 AM EDT - 2 months ago

FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients

May 23, 2025, 4:05 PM EDT - 3 months ago

CEL-SCI Announces Closing of Public Offering

May 21, 2025, 8:14 PM EDT - 3 months ago

CEL-SCI Announces Pricing of Public Offering

May 21, 2025, 8:00 AM EDT - 3 months ago

CEL-SCI's Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia

May 19, 2025, 2:40 PM EDT - 3 months ago

CEL-SCI Announces Combination of Common Stock

May 15, 2025, 9:00 AM EDT - 4 months ago

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results

Apr 23, 2025, 8:30 AM EDT - 4 months ago

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

Apr 8, 2025, 9:51 AM EDT - 5 months ago

New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

Mar 24, 2025, 9:00 AM EDT - 5 months ago

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

Mar 18, 2025, 4:05 PM EDT - 6 months ago

CEL-SCI Announces Closing of $2.5 Million Offering

Mar 17, 2025, 3:24 PM EDT - 6 months ago

CEL-SCI Announces Pricing of $2.5 Million Offering

Mar 17, 2025, 8:00 AM EDT - 6 months ago

CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine

Mar 14, 2025, 8:30 AM EDT - 6 months ago

Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

Feb 20, 2025, 8:00 AM EST - 7 months ago

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

Feb 18, 2025, 8:30 AM EST - 7 months ago

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

Jan 14, 2025, 9:00 AM EST - 8 months ago

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer

Dec 31, 2024, 4:05 PM EST - 8 months ago

CEL-SCI Announces Closing of $5 Million Offering

Dec 29, 2024, 8:41 PM EST - 9 months ago

CEL-SCI Announces Pricing of $5 Million Public Offering

Dec 27, 2024, 5:05 PM EST - 9 months ago

CEL-SCI Announces Proposed Public Offering of Common Stock

Dec 12, 2024, 9:15 AM EST - 9 months ago

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

Nov 8, 2024, 8:00 AM EST - 10 months ago

Stock Picks From Seeking Alpha's October 2024 New Analysts

ACGL AMCX AMPS APOG AVRE BHP BILL

Nov 7, 2024, 8:15 AM EST - 10 months ago

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

Oct 22, 2024, 9:15 AM EDT - 11 months ago

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

Oct 1, 2024, 6:00 AM EDT - 1 year ago

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

Sep 16, 2024, 7:30 AM EDT - 1 year ago

CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

Sep 10, 2024, 9:32 AM EDT - 1 year ago

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

Sep 4, 2024, 9:00 AM EDT - 1 year ago

The UK's Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

Aug 15, 2024, 8:00 AM EDT - 1 year ago

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

Jul 29, 2024, 4:05 PM EDT - 1 year ago

CEL-SCI Announces Closing of $10.8 Million Offering

Jul 26, 2024, 11:52 AM EDT - 1 year ago

CEL-SCI Announces Pricing of $10.8 Million Offering

Jul 26, 2024, 8:23 AM EDT - 1 year ago

CEL-SCI's Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results

Jul 8, 2024, 9:15 AM EDT - 1 year ago

CEL-SCI Appoints Robert Watson as Chairperson of the Board

Jun 18, 2024, 8:00 AM EDT - 1 year ago

CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

May 16, 2024, 9:00 AM EDT - 1 year ago

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results

May 8, 2024, 9:00 AM EDT - 1 year ago

CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer

Apr 23, 2024, 9:00 AM EDT - 1 year ago

CEL-SCI Appoints Mario Gobbo to Its Board of Directors

Apr 16, 2024, 9:00 AM EDT - 1 year ago

Channel V Media Expands Content Marketing Division; Names Gabriella Bock Director of Content

Mar 19, 2024, 9:00 AM EDT - 1 year ago

CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology

Mar 6, 2024, 8:45 AM EST - 1 year ago

CEL-SCI Corporation Issues Letter to Shareholders

Feb 15, 2024, 8:00 AM EST - 1 year ago

CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results

Feb 13, 2024, 12:00 PM EST - 1 year ago

CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock

Dirk1969 Sep. 8 at 8:27 AM

0 · Reply

A416 Sep. 8 at 2:34 AM

$CVM Multikine&#39;s Breakthrough Approvals and Saudi Market Entry. https://youtu.be/dhGTQbVFyuE

1 · Reply

CurlingCalls Sep. 7 at 11:46 PM

$CVM

0 · Reply

CurlingCalls Sep. 7 at 11:45 PM

$CVM so what do we got this week? Besides IPOs of course

0 · Reply

Dirk1969 Sep. 7 at 5:52 PM

$CVM https://www.sec.gov/ix?doc=/Archives/edgar/data/0000725363/000165495425009966/cvm_8k.htm

0 · Reply

Dirk1969 Sep. 7 at 5:33 PM

$CVM ✅📈 https://youtu.be/u3vhTLg62-w?si=YzjblXe3fbeWKD1R

0 · Reply

Dirk1969 Sep. 7 at 5:30 PM

$CVM scroll through👇🏽 https://www.corporateprofile.com/media/

0 · Reply

Dirk1969 Sep. 7 at 5:25 PM

1 · Reply

cruiser24 Sep. 7 at 12:40 AM

$CVM Perhaps it would serve you well to do some research on Dallah-pharma

0 · Reply

cruiser24 Sep. 7 at 12:24 AM

$CVM Aging like a fine wine. Just waiting for the right time to pop the cork. BULLISH

1 · Reply

cruiser24 Sep. 6 at 1:06 PM

$CVM BULLISH https://www.dallah-pharma.com Found ut interesting reading about Dallah Parma on its own site hiw clisely Cel-sci fit in with Dallah’s goals. Especially interesting was reading about their desire to imprive patients quality of life. Also to find them a company of high integrity reminded me once again why I remain so deficated to the advsncement of the company Cel-sci. iI jeep reminding myself that afyer all these years, sometimes seeming too many, that even though there are many times Geery is teferred to as a on man, sinething just doesn fit. No lawsuits. CVM BULLISH

3 · Reply

andreg_26 Sep. 5 at 6:18 PM

$CVM

0 · Reply

Thebullrun Sep. 5 at 6:12 PM

$CVM let’s rock n roll!!

0 · Reply

CashNCarry Sep. 5 at 4:06 PM

$CVM

0 · Reply

Dirk1969 Sep. 5 at 3:58 PM

$CVM in the green within an hour ✅📈

1 · Reply

andreg_26 Sep. 5 at 2:32 PM

$CVM very healthy pullback, do not forget this was at low $8’s after the offering. Watching even the 3 month trend, it is a very visible positive trend. Patience‼️🗣️

1 · Reply

Freetimeod Sep. 5 at 2:29 PM

$CVM more and more I am believing the “Saudi” partnership was total bullshit in order to boost price for an offering. You don’t tell people something is “imminent” and let months go by with no word. Unless, of course, you are Geert where “what’s the big deal, I am already in this thing 43 years”. Not a big deal if you are being paid a million a year those 43 years, and not accomplishing a fucking thing but stringing your investors on.

0 · Reply

TonyLA Sep. 5 at 2:14 PM

$CVM Bye bye 11 see ya at 5! The shady lawyer strikes again! 🤡😂

1 · Reply

TonyLA Sep. 5 at 1:56 PM

$CVM Stinker going back to stinking! The shady lawyer strikes again!

1 · Reply

Dirk1969 Sep. 5 at 1:55 PM

$CVM now we're waiting for good news ✅📈

0 · Reply

phoenix31415 Sep. 5 at 10:38 AM

$CVM Yesterday's daily short sale volume was 46.93% (as reported by FINRA) and it seems that the shorts are trying hard to manipulate the market! The short borrow fee is at 49.80% and the number of currently shorted shares has further increased to 1.04 million shares — that is 15.3% of the Float!! Furthermore, the short shares availability is 300'000. With the recent SFDA developments (Breakthrough Medicine Designation application has been filed with the SFDA) and partner developments (Dallah Pharma), we might see a potential sale of Multikine in SA by early fall 2025 (early October, yes that's less than 4 weeks!!) as stated in Cel-Sci's latest corporate slide presentation from August (available on their website). I am so happy for all the cancer patients who will hopefully soon be able to profit from Multikine! GLTAL!!

0 · Reply

MTRADe_01 Sep. 5 at 5:02 AM

$STEM $CVM $SST $UP $INMB

1 · Reply

Market Cap	72.19M
Revenue (ttm)	0.00
Net Income (ttm)	-26.92M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	223,800
Avg Vol	966,620
Day's Range	N/A - N/A
Shares Out	6.88M
Stochastic %K	38%
Beta	0.54
Analysts	Strong Sell
Price Target	$180.18